These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32854121)

  • 1. High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study.
    Toorop MMA; van Rein N; Cannegieter SC; van der Meer FJM; Reitsma PH; Lijfering WM; Bos MHA
    Thromb Haemost; 2021 Jan; 121(1):70-75. PubMed ID: 32854121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombomodulin as a marker for bleeding complications during warfarin treatment.
    Lind M; Boman K; Johansson L; Nilsson TK; Ohlin AK; Birgander LS; Jansson JH
    Arch Intern Med; 2009 Jul; 169(13):1210-5. PubMed ID: 19597070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.
    Veeger NJ; Piersma-Wichers M; Meijer K; Hillege HL
    Br J Haematol; 2011 May; 153(4):508-14. PubMed ID: 21418182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of major bleeding after a minor bleed during treatment with vitamin K antagonists is determined by fixed common risk factors.
    van Rein N; le Cessie S; van Vliet IP; Reitsma PH; van der Meer FJ; Lijfering WM; Cannegieter SC
    J Thromb Haemost; 2016 May; 14(5):948-52. PubMed ID: 26988994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists.
    Mathieu E; Van Dreden P; Aulagnier J; Grusse M; Dreyfus JF; François D; Vasse M
    Thromb Res; 2016 Jan; 137():36-40. PubMed ID: 26632514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.
    van der Heijden JF; Rekké B; Hutten BA; van der Meer FJ; Remkes MG; Vermeulen M; Büller HR; Reitsma PH
    J Thromb Haemost; 2004 Jul; 2(7):1104-9. PubMed ID: 15219193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.
    Karrowni W; Wang TY; Chen AY; Thomas L; Saucedo JF; El Accaoui RN
    Heart; 2015 Feb; 101(4):264-70. PubMed ID: 25336230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.
    Henkens IR; Hazenoot T; Boonstra A; Huisman MV; Vonk-Noordegraaf A
    Eur Respir J; 2013 Apr; 41(4):872-8. PubMed ID: 22936704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study.
    Pastori D; Carnevale R; Cangemi R; Saliola M; Nocella C; Bartimoccia S; Vicario T; Farcomeni A; Violi F; Pignatelli P
    J Am Heart Assoc; 2013 Oct; 2(6):e000364. PubMed ID: 24166490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment.
    Jansson JH; Boman K; Brännström M; Nilsson TK
    Circulation; 1997 Nov; 96(9):2938-43. PubMed ID: 9386160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
    Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
    Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
    Hutten BA; Prins MH; Gent M; Ginsberg J; Tijssen JG; Büller HR
    J Clin Oncol; 2000 Sep; 18(17):3078-83. PubMed ID: 10963635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.